Newsroom
Featured News
- Investors10 April 2025
Lotus Announces Share Buyback Program to Enhance Shareholder Value
- Investors08 April 2025
Lotus Pharmaceutical Reaches New Height of First Quarter Revenue of NT$4.73 Billion
- Business10 March 2025
Lotus Reported Unaudited February Revenues of NT$967 Million
- Investors06 March 2025
Lotus sets new heights in 2024, achieving six consecutive years of double-digit growth
- Business20 February 2025
Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis®
- Business11 February 2025
Lotus Announces TFDA Approval for Adcirca® (Tadalafil) for PAH Treatment
- Investors10 February 2025
Lotus Reported Unaudited January Revenues of NT$2,171 million
- Investors10 January 2025
Lotus Achieves Historical High with Unaudited 2024 Revenue of NT$18.6 Billion
- Business07 January 2025
Lotus Announces the Closing of the Alphachymotrypsine Choay® Acquisition, Ready to consolidate revenue from Q1 2025
